Navigation Links
Cold winters freezing out breast cancer treatment
Date:4/18/2013

LONDON, ON For women diagnosed with a form of breast cancer known as estrogen receptor positive (ER+) breast cancer, tamoxifen is an essential drug used in the treatment and prevention of recurring breast cancer. Currently, tamoxifen is used in a one-size-fits-all approach where the same dose is prescribed for every patient. New research at Lawson Health Research Institute has found that in addition to patient-specific genetic factors, lack of exposure to vitamin D during the long winter months affects the body's ability to metabolize the drug.

The findings, which have been reported in the journal Breast Cancer Research and Treatment, are the first to identify this seasonal effect. Dr. Richard Kim, who is a physician at London Health Sciences Centre (LHSC) and holds the Wolfe Medical Research Chair in Pharmacogenomics at Western University, reports that during the winter months nearly 30 percent of patients are at risk for less than optimal level of the active form of tamoxifen, called endoxifen, and therefore may not benefit as much from the therapy.

In the liver, tamoxifen is converted to the active form of the drug called endoxifen by a protein called CYP2D6. "We know that endoxifen is nearly 100 times more potent against the estrogen receptor relative to tamoxifen," says Dr. Kim. "Our research has shown that patients with normal CYP2D6 activity can easily convert tamoxifen to endoxifen, whereas patients with no CYP2D6 activity have a significantly limited ability to convert tamoxifen to endoxifen."

In addition to the seasonal effect, Dr. Kim found that the simultaneous use of a common antidepressant can also substantially lower the body's ability to metabolize endoxifen levels. "Patients who are either partly or completely deficient in CYP2D6 and who are prescribed the SSRI class of antidepressants are at major risk for subtherapeutic endoxifen levels," says Dr. Kim.

With nearly 10 percent of the population completely lacking CYP2D6 enzymatic activity, these findings have important clinical applications. "Our most recent findings are important additions to the pool of data we already have on tamoxifen therapy," says Dr. Kim. "These new clinical and genetic markers can aid physicians to better identify patients who will benefit from tamoxifen, as well as those patients at risk for suboptimal benefit."


'/>"/>

Contact: Robert DeLaet
robert.delaet@lawsonresearch.com
519-685-8500 x75616
Lawson Health Research Institute
Source:Eurekalert

Related biology news :

1. Duck-billed dinosaurs endured long, dark polar winters
2. Extreme winters impact fish negatively
3. Freezing nerves knocks pain out cold
4. Protein jailbreak helps breast cancer cells live
5. Breast cancer risk gene discovery fast tracked by new technology
6. A new breast cancer susceptibility gene
7. Mechanism found connecting metastatic breast cancer and arthritis
8. Detecting breast cancers fingerprint in a droplet of blood
9. Researchers identified a protein useful in predicting the risk of pulmonary metastases in breast cancer patients
10. High levels of TRAIL protein in breast milk might contribute to anticancer activity
11. Fourth IMPAKT Breast Cancer Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- BioCatch , the global leader in behavioral biometrics, ... grew to over 40 granted and pending patents. ... , , The Company,s IP ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... costly hardware components needed to estimate the force and pressure applied to ...
(Date:12/7/2016)... 2016   Veridium , a leader in ... new CEO James Stickland . Stickland, a ... experience, has served in senior executive roles for ... in expanding a pipeline of venture capital and ... recently served as managing director of U.K.-based fintech ...
(Date:12/6/2016)... Valencell , the leading innovator in performance biometric ... consecutive year of triple digit growth for its PerformTek ... 360 percent increase in companies who have acquired Valencell ... sales of its wrist and ear Benchmark™ sensor systems, ... hearables for fitness and healthcare applications. ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... ... 09, 2016 , ... DuPont Industrial Biosciences (DuPont) and Archer ... Year Award from Platts Global Energy for their platform technology to produce ... at the 18th Platts Global Energy Awards, held in New York on Thursday, Dec. ...
(Date:12/9/2016)... , December 9, 2016 The ... top five players in the  Global Label-Free Array Systems ... overall market in 2015. Players such as Biacore, Agilent ... remained dominant in the global market due to their ... product innovation. Product upgrades and timely product launches are ...
(Date:12/9/2016)... KONG , Dec. 9, 2016 China Cord ... "Company"), China,s leading provider of cord ... cell storage services, today announced the results of its 2016 ... in Hong Kong S.A.R., China . ... ratified the re-appointment of KPMG Huazhen LLP as ...
(Date:12/9/2016)... 9, 2016 According to a new market ... Custom, Predesigned, Reagent Equipment), Application (Research, PCR, Gene, DNA, NGS, Diagnostic, ... by MarketsandMarkets, the global market is expected to reach USD 2.20 ... CAGR of 10.6% during the forecast period. ... ...
Breaking Biology Technology: